MaxCyte, Inc. Share

MaxCyte, Inc. is a global cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research, development, and commercialization of novel cell therapies. The company's proprietary Flow Electroporation® technology facilitates complex engineering of cells, supporting a wide range of applications across the biopharmaceutical industry, including gene editing, immunotherapy, and protein expression. MaxCyte partners with leading drug developers and academic institutions to accelerate the discovery and delivery of potentially life-saving treatments. Their technology addresses critical challenges in cell therapy manufacturing, enabling efficient and scalable production of engineered cells for clinical and commercial use. By providing advanced tools and expertise, MaxCyte contributes to the advancement of cell-based medicines and the improvement of patient outcomes.